Company Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer.
Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers.
It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer.
Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
Country | United States |
Founded | 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 140 |
CEO | Dr. Barbara L. Weber M.D. |
Contact Details
Address: 201 Brookline Avenue, Suite 901 Boston, Massachusetts 02215 United States | |
Phone | (857) 320-4900 |
Website | tangotx.com |
Stock Details
Ticker Symbol | TNGX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001819133 |
CUSIP Number | 87583X109 |
ISIN Number | US87583X1090 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Barbara L. Weber M.D. | President, Chief Executive Officer and Director |
Daniella Beckman CPA | Chief Financial Officer |
Dr. Alan Ashworth FRS, Ph.D. | Founder and Member of Scientific Advisory Board |
Dr. Levi Garraway M.D., Ph.D. | Founder |
Dr. William G. Kaelin Jr., M.D. | Founder and Member of Scientific Advisory Board |
Dr. Timothy K. Lu M.D., Ph.D. | Founder |
Dr. Antoni Ribas M.D., Ph.D. | Founder and Member of Scientific Advisory Board |
Jannik N. Andersen Ph.D. | Chief Scientific Officer |
Douglas J. Barry Esq., J.D. | Chief Legal Officer, Chief Compliance Officer and Corporate Secretary |
John C. Ross M.S. | Vice President of Human Resources |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 17, 2024 | PRE 14A | Other preliminary proxy statements |
Apr 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Mar 18, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 18, 2024 | 10-K | Annual Report |
Mar 18, 2024 | 8-K | Current Report |
Feb 21, 2024 | 144 | Filing |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 7, 2024 | 8-K | Current Report |